Trial Profile

A Phase II study of Pritumumab for the treatment of Brain Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2024 According to Nascent Biotech media release, the FDA has cleared clinical trial application to begin this Phase II study for the treatment of Brain Cancer.
18 Apr 2023 According to Nascent Biotech media release, the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab; Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB has also been submitted to the FDA. company anticipates initial comments from the FDA approximately 30 days from the date of filing.
16 Sep 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com